EMA Initiates Phased Review of Revolution Medicines' Daraxonrasib for Metastatic Pancreatic Cancer

A sequenced data submission strategy is now live at the European level: EMA's Committee for Medicinal Human Products (CHMP) has opened a phased review of daraxonrasib, Revolution Medicines' RAS inhibitor targeting metastatic pancreatic cancer, allowing quality, nonclinical, and clinical packages to be assessed as each becomes available rather than waiting for a complete marketing authorisation application. For regulatory affairs leads and QA directors preparing EU submissions, this case establishes a working template for how phased reviews will operate under the reformed EU pharmaceutical legislation.

The trigger for CHMP's decision was Phase 3 data comparing daraxonrasib against chemotherapy in previously treated metastatic pancreatic cancer patients, a population with a median life expectancy of approximately six months and limited second-line options. EMA had already recognised daraxonrasib under its Cancer Medicines Pathfinder project and expedited its eligibility for centralised marketing authorisation, reflecting the significant unmet medical need. Orphan designation was granted on 20 April 2026 (EU/3/26/3227).

The procedural architecture here carries direct implications for submission planning. Under a phased review, the CHMP begins assessment before the full dossier is complete, compressing the overall evaluation timeline without relaxing the standards applied under 21 CFR Part 211 equivalents or ICH quality benchmarks. EMA has confirmed that medicines assessed via this pathway are held to identical quality, safety, and efficacy standards as those entering standard centralised procedures. The overall timeline for daraxonrasib remains unquantified, though EMA states it is expected to be shorter than a conventional evaluation.

EMA has signalled that daraxonrasib will serve as a reference case for provisions in the reformed EU pharmaceutical legislation, which is expected to formalise and expand phased review use. Future candidates will be considered on a case-by-case basis, with eligibility contingent on unmet medical need and significant public health interest, particularly around therapeutic innovation. Regulatory teams tracking pipeline assets with orphan or breakthrough profiles should factor phased review eligibility assessments into their EU regulatory strategy timelines now, before the legislative provisions are fully enacted.

Daraxonrasib also falls within scope of the EU Health Technology Assessment Regulation, meaning a parallel joint clinical assessment coordinated by the HTA Secretariat within the European Commission will proceed independently of EMA's marketing authorisation review, adding a second concurrent evaluation track that submission teams will need to resource accordingly.

The measurable checkpoint ahead is the point at which Revolution Medicines submits its complete marketing authorisation application, at which stage the proportion of assessment already completed under the phased review will determine the net timeline compression actually achieved.

Source: European Medicines Agency (EMA) via ema.europa.eu, 7 July 2026.